Estrogen and insulin crosstalk: breast cancer risk implications

Nurse Practitioner

Volumn 28, Issue 5, 2003, Pages 12-23

  McCance, Kathryn L ^a   Jones, Robert E ^b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; INSULIN; OMEGA 3 FATTY ACID; SOMATOMEDIN;

BREAST TUMOR; DIET; DIETARY FIBER; EXERCISE; FEMALE; HUMAN; HYPERINSULINISM; INSULIN RESISTANCE; LIFESTYLE; MENOPAUSE; OBESITY; PHYSIOLOGY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; DIET; DIETARY FIBER; ESTROGENS; EXERCISE; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; LIFE STYLE; MENOPAUSE; OBESITY; RISK FACTORS; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 0038409832     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/00006205-200305000-00004     Document Type: Article

References (65)

1. Brown PH, Lippman SM: Chemoprevention of breast cancer. Breast Cancer Res Treat 2000; 62(1):1-17.
2. Stoll BA: Biological mechanisms in breast cancer invasiveness: relevance to preventive interventions. Eur J Cancer Prev 2000; 9(2):73-9.
3. Solomon CG: The epidemiology of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28:247-63.
4. Bruning PF, Bonfrer JM, van Noord PA, et al: Insulin resistance and breast cancer risk. Int J Cancer 1992; 52:511-6.
5. Del Giudice ME, Fantus IG, Ezzat S, et al: Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998; 47:111-20.
6. Stoll BA: Western nutrition and the insulin resistance syndrome: a link to breast cancer. Eur J Clin Nutr 1999; 53:83-7.
7. Yang G, Lu G, Jin F, et al: Population-based, case-control study of blood C-peptide level and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10:1207-11.
8. Stoll BA: Adiposity as a risk determinant for postmenopausal breast cancer. Int J Obes Relat Metab Disord 2000; 24(5):527-33.
9. Stoll BA: Estrogen/insulin-like growth factor-I receptor interaction in early breast cancer: clinical implications. Ann Oncol 2002; 13(2):191-6.
10. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Onc 2002; 20:42-51.
11. Stoll BA: Breast cancer: further metabolic-endocrine risk markers? Br J Cancer 1997; 76(12):1652-4.
12. Yee D, Lee AV: Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia, 2000; 5(1):107-15.
13. Osborne CK, et al: Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001; 7(12 Suppl):4338s-42s.
14. Zhang X, Yee D: Tyrosine kinase signaling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2000; 2(3):107-5.
15. Kato S: Estrogen receptor-mediated cross talk with growth factor signaling pathway. Breast Cancer 2001; 8(1):3-9.
16. Nicholson RI, et al: Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann NY Acad Sci 2002; 963:104-15.
17. Lee AN, Cui X, Osterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 2001; 7 (12 Suppl):4429s; discussion 4411s-12s.
18. Dupont J, LeRoith D: Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 2001; 54(3):149-54.
19. Kari FW, et al: Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction. J Nutr Health Aging 1999; 3(2):92-101.
20. Westley BR, et al: Interactions between the oestrogen and insulin-like growth factor signaling. Biochem Soc Symp 1998; 63:35-44.
21. Rozen F, Pollack M: Inhibition of insulin-like growth factor 1 receptor signaling by the vitamin D analogue EB 1089 in MCF-7 breast cancer cells: a role for insulin-like growth factor binding proteins. Int J Oncol 1999; 15:589-94.
22. Baxter RC, Saunders H: Radioimmunoassay of insulin-like growth factor (IGF)-binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem 1992; 267:22467-72.
23. Djavan B, et al: Insulin-like growth factors and prostate cancer. World J Urol 2001; 189:225-33.
24. Lee AV, et al: Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999; 13:787-96.
25. Sachdev D, Yee D: The IGF system and breast cancer. Endocr Relat Cancer 2001; 8:197-209.
26. Zumkeller W: IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth? J Clin Pathol 2001; 54:298-8.
27. Pollack MN: Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 1998; 47:209-17.
28. Yee AV, Darbre P, King RJ: Processing of insulin-like growth factor II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol 1994; 99:211-20.
29. Moschas SJ, Mantzoros CS: The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 2002; 63(4):317-32.
30. Sachden D, Yee D: The IGF system and breast cancer. Endocrin Relat Cancer 2001; 8(3):197-209.
31. Yee D: The insulin-like growth factor system as a treatment target in breast cancer. Semin Oncol 2002; 29(2 Suppl 11):86-95
32. Wang Y, Sun Y: Insulin-like growth factor receptor-1 as an anticancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2002; 2(3):191-207.
33. D’Ambrosio C, et al: Transforming potential of the insulin receptor substrate 1. Cell Growth Differ 1995; 6:557-62.
34. Jackson JG et al: Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 2001; 20(50):7318-7325.
35. Oesterreich S, et al: Re-expression of estrogen receptor a in estrogen receptor a-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 2001; 651(15):5771-7.
36. Woodward TL, Lu H, Haslam SZ: Lamin inhibits estrogen action in human breast cancer cells. Endocrinol 2000; 141(8):2814-21.
37. Leboff MS, et al: (1995). Changes in growth factors and cytokines in postmenopausal women [Abstract]. J Bone Miner Res 1995; 10:241.
38. Poehlman ET, et al: Menopause-associated changes in plasma lipids, insulin-like growth factors I and blood pressure: a longitudinal study. Eur J Clin Invest 1997; 4:322-6.
39. Cardim HJ, et al: The insulin-like growth factor-1 system and hormone replacement therapy. Fertil Steril 2001; 75(2):282-7.
40. Ho KKY, Weissberger AJ: Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. J Bone Miner Res 1992; 7:821-7.
41. Jernström H, Barrett-Connor E: Obesity, weight change, fasting insulin, proinsulin, c-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Women’s Hlth Gend Based Med 1999; 8(10):1265-72.
42. Slowinska-Srzednicka J, et al: Transdermal 17 beta estradiol combined with oral progestogen increases plasma levels of IGF-I in postmenopausal women. J Endocrinol Invest 1992; 15:533-8.
43. Weissberger AJ, et al: Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone secretion, insulin-like growth factor-I, and growth hormone-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991; 72:374-81.
44. Donahue LR, et al: Age-related changes in serum IGF binding proteins in women. J Clin Endocrinol Metab 1990; 71:575-9.
45. Kam GVW, et al: Estrogens exert route and dose-dependent effects on insulin-like growth factor (IGF) binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 2000; 8(5):1918-22.
46. Bellantoni MF, et al: Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 1996; 81(8):2848-53.
47. Campagnoli C, et al: Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993; 7(4):251-8.
48. Cano A, Costelo-Branco C, Tarin JJ: Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP-1), and IGFBP-3 levels. Fertil Steril 1999; 71(2):261-7.
49. Heald A, et al: Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am J Obstet Gynecol 2000; 183(3):593-600.
50. Helle SI, et al: Effects of oral and transdermal estrogen replacement therapy on plasma levels of insulun-like growth factors and IGF-binding proteins 1 and 3: a crossover study. Clin Endocrinol (Oxf) 1996; 45(6):727-32.
51. Paasilta M, et al: Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-1 during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. Atherosclerosis 2000; 149(1):157-62.
52. Raudaskoski T, Knip M, Laatikainen T: Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy. Menopause 1998; 5(4):217-22.
53. Wilson ME: Administration of IGF-1 affects the GH axis and adolescent growth in normal monkeys. J Endocrinol 1997; 153(2):327-35.
54. Zhang X, Yee D: Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer motility. Cancer Res 2002; 62(15):4369-75.
55. Holdaway IM, et al: Effect of breast surgery on serum levels of insulin-like growth factors (IGF-I, IGF-II, and IGF binding protein-3) in women with benign and malignant breast lesions. Ann Surg Oncol 2001; 8:25-31.
56. Kaulsey KK, et al: Serum IGF-binding protein-6 and prostate specific antigen in breast cancer. Eur J Endocrinol 1999; 140:164-8.
57. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46:3-10.
58. Plymate SR, Matje LA, Jones RE, Friedl KE: Inhibition of sex hormone binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988; 67:460-4.
59. McTernan PG, Anwar A, Eggo MC, et al: Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. Int J Obes Relat Metab Disord 2000; 24:875-81.
60. Cohen P, Clemmon DR, Rosenfeld RG: Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000; 10:297-305.
61. Bocchinfusso WP, Korack KS: Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 1997; 2:323-34.
62. Ruan W, et al: Estradiol enhances the stimulatory effect of insulin-like growth factor-1 (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 1995; 136:1296-1302.
63. Ruan W, Kleinberg DL: Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 1999; 140:5075-81.
64. Kleinman D, et al: Modulation of insulin-like growth factor (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol. Endocrinology 1995; 136:2531-7.
65. Richards RG, et al: Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. Proc Natl Acad Sci USA 1996; 93:12002-7.